menu
    • menu
    [{"orgOrder":0,"company":"CHIESI USA INC","sponsor":"Apotex Inc","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Deferiprone","moa":"Iron","graph1":"Genetic Disease","graph2":"Approved","graph3":"CHIESI USA INC","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"CHIESI USA INC \/ Chiesi Group","highestDevelopmentStatusID":"12","companyTruncated":"CHIESI USA INC \/ Chiesi Group"},{"orgOrder":0,"company":"CHIESI USA INC","sponsor":"Bioasis","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"Transcend-peptide","moa":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"CHIESI USA INC","amount2":0.14000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"CHIESI USA INC \/ Chiesi Group","highestDevelopmentStatusID":"1","companyTruncated":"CHIESI USA INC \/ Chiesi Group"},{"orgOrder":0,"company":"CHIESI USA INC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Mannitol API","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"CHIESI USA INC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for inhalation","sponsorNew":"CHIESI USA INC \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CHIESI USA INC \/ Not Applicable"},{"orgOrder":0,"company":"CHIESI USA INC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cangrelor","moa":"P2Y12 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"CHIESI USA INC","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CHIESI USA INC \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CHIESI USA INC \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by CHIESI USA INC

    Menu

    CHIESI USA INC

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CHIESI USA INC

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            CHIESI USA INC

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cangrelor

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chiesi USA Announces First Analysis from the CAMEO Registry Assessing KENGREAL (cangrelor) Use and Transition ...

                            Details : KENGREAL (cangrelor) for Injection is a P2Y12 platelet inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce risk of MI, repeat coronary revascularization, and stent thrombosis (ST) in patients.

                            Brand Name : Kengreal

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 01, 2022

                            Lead Product(s) : Cangrelor

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CHIESI USA INC

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            CHIESI USA INC

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mannitol API

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chiesi Announces Commercial Availability of Bronchitol Inhalation Powder for Improvement in Pulmonary Function...

                            Details : In the multicenter, double-blind, randomized, parallel-group, controlled study of 423 adults with CF, subjects received either mannitol 400mg or mannitol 50mg (control), twice-daily via dry powder inhaler for 26 weeks.

                            Brand Name : Bronchitol

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 17, 2021

                            Lead Product(s) : Mannitol API

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            CHIESI USA INC

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            CHIESI USA INC

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Transcend-peptide

                            Therapeutic Area : Genetic Disease

                            Study Phase : Undisclosed

                            Recipient : Bioasis

                            Deal Size : $141.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Bioasis and Chiesi Group Announce Rare Diseases Strategic Alliance

                            Details : The unique delivery method of their xB3 platform has the potential to overcome a significant challenge in the treatment of many neurological disorders, which is the ability to cross the blood brain barrier.

                            Brand Name : xB3

                            Molecule Type : Peptide

                            Upfront Cash : $3.0 million

                            June 29, 2020

                            Lead Product(s) : Transcend-peptide

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Undisclosed

                            Recipient : Bioasis

                            Deal Size : $141.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            CHIESI USA INC

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            CHIESI USA INC

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deferiprone

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Recipient : Apotex Inc

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Chiesi Group and Apotex Inc. finalize agreement for acquisition of Ferriprox® (deferiprone)

                            Details : Chiesi Group expands distribution network via acquisition for worldwide product rights.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 13, 2020

                            Lead Product(s) : Deferiprone

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Recipient : Apotex Inc

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth